Statements (59)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:Regeneron_Pharmaceuticals
|
| gptkbp:activities |
inhibits PCS K9 protein
|
| gptkbp:appointed_by |
subcutaneous injection
|
| gptkbp:approves |
gptkb:2015
gptkb:FDA |
| gptkbp:associated_with |
improved quality of life
reduced risk of cardiovascular death reduced risk of heart attack reduced risk of stroke |
| gptkbp:can_be_used_with |
statins
certain monoclonal antibodies other PCS K9 inhibitors |
| gptkbp:class |
PCS K9 inhibitor
|
| gptkbp:clinical_trial |
gptkb:ODYSSEY_trials
Phase III hyperlipidemia |
| gptkbp:contraindication |
hypersensitivity to alirocumab
|
| gptkbp:dosage_form |
injection solution
|
| gptkbp:duration |
ongoing
|
| gptkbp:education |
important for understanding use
|
| gptkbp:events |
recommended after initiation
|
| https://www.w3.org/2000/01/rdf-schema#label |
Praluent
|
| gptkbp:indication |
gptkb:atherosclerotic_cardiovascular_disease
heterozygous familial hypercholesterolemia |
| gptkbp:influenced_by |
diet and lifestyle changes
|
| gptkbp:ingredients |
gptkb:alirocumab
|
| gptkbp:interacts_with |
limited interactions
|
| gptkbp:invention |
2026
|
| gptkbp:is_available_in |
various dosages
|
| gptkbp:is_available_on |
auto-injector
pre-filled syringe |
| gptkbp:is_effective_against |
reduces LDL cholesterol
reduces cardiovascular events |
| gptkbp:is_monitored_by |
liver function tests
lipid levels |
| gptkbp:is_used_for |
lowering cholesterol
|
| gptkbp:manager |
subcutaneous
|
| gptkbp:manufacturer |
gptkb:Sanofi
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:United_States gptkb:Native_American_tribe gptkb:brand |
| gptkbp:population |
adults
|
| gptkbp:price |
varies by insurance
|
| gptkbp:provides_information_on |
included in treatment guidelines
|
| gptkbp:requires |
available online
|
| gptkbp:research_focus |
cost-effectiveness
compliance strategies long-term outcomes |
| gptkbp:side_effect |
fatigue
muscle pain allergic reactions diarrhea injection site reactions liver enzyme elevations |
| gptkbp:storage |
refrigerated
|
| gptkbp:type_of_care |
important for efficacy
|